Mouhammed Habra, MD
Basic profileMouhammed Habra is an Endocrinology/Metabolic physician affiliated with The University of Texas MD Anderson Cancer Center. OpenAlex indexes 232 publications with 9,946 citations (h-index 47); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingClinical trials
- Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma
Sponsor: M.D. Anderson Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ExelixisProgram year20251 paymentResearch$20,064
- RECORDATI_RARE_DISEASES_INC.Program year20251 payment$3,850
- Merck & Co.Program year20241 paymentResearch$111,150
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Hormonal (systemic)
64.1%l-Thyroxine60.6%Levothyroxine Sodium80%Synthroid20%Part D≥61 patientsVasopressin Analog3.5%Desmopressin Acetate100%Part D<11 patientsCancer & immunology
13.7%Kinase inhibitor9.2%Lenvima52%Tafinlar48%Part D<11 patientsOther antineoplastic agents4.4%Lysodren100%Part D<11 patientsSensory organs
8.3%Corticosteroid8.3%Hydrocortisone100%Part D≥15 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns
Endocrine Related Cancer
2021 - Phase 2 study of pembrolizumab in patients with advanced rare cancers
Journal for ImmunoTherapy of Cancer
2020 - Objective Response and Prolonged Disease Control of Advanced Adrenocortical Carcinoma with Cabozantinib
The Journal of Clinical Endocrinology & Metabolism
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Anil Sood, MD
The University of Texas MD Anderson Cancer Center
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Yousef Saleh Khader
Jordan University of Science and Technology
Jens Juul Holst
University of Copenhagen
Victor Montori, MD
Mayo Clinic
Christos Mantzoros, MD
Harvard Medical School
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”